Salvianolate inhibits reactive oxygen species production in H2O2-treated mouse cardiomyocytes in vitro via the TGF|[beta]| pathway
Ai-hua Fei,Qing Cao,Shu-yan Chen,Hai-rong Wang,Fei-long Wang,Shu-ming Pan,Zhao-fen Lin
DOI: https://doi.org/10.1038/aps.2012.209
IF: 7.169
2013-01-01
Acta Pharmacologica Sinica
Abstract:Congestive heart failure (CHF) is a major cause of cardiac morbidity and mortality world-wide. Recent experimental and clinical studies have suggested that oxidative stress plays an important role in myocardial remodeling and heart failure1,2. The increased production of oxygen radicals in the failing heart has been linked to the development of left ventricular hypertrophy and heart failure progression. Reactive oxygen species (ROS) cause contractile failure and structural damage in the myocardium. The importance of oxidative stress is emerging with respect to a pathophysiological mechanism of LV remodeling responsible for heart failure progression. Transforming growth factor beta (TGFβ) is an important fibrogenic growth factor. TGFβ can induce renal extracellular matrix (ECM) accumulation and organ fibrosis, including cardiac fibrosis in chronic heart failure patients. ROS is a signaling molecule that mediates the effects of TGFβ1. TGFβ1 induces prolonged mitochondrial ROS generation in Mv1Lu cells3. Elevated systemic TGFβ impairs aortic vasomotor function through the activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(−/−) mouse4. Salvianolate is a newly discovered water-soluble phenolic compound that is one of the most bioactive compounds in Salvia miltiorrhiza Bunge. As a highly purified aqueous extract from Danshen, salvianolate contains mainly magnesium lithospermate B (≥85%), rosmarinic acid (≥10.1%) and lithospermic acid5,6. Salvianolate inhibits cytokine gene expression in the small intestine of cirrhotic rats5. Salvianolate can inhibit cardiomyocytic apoptosis and improve heart function after acute myocardial infarction (AMI) in swine7. To date, the effect of salvianolate on ROS production in cardiomyocytes remains unknown. In this study, we aimed to investigate whether salvianolate influences ROS production in cardiomyocytes undergoing H2O2-induced oxidative damage. We also explored the role of the TGF signaling pathway in the regulation of H2O2-induced ROS injury and whether this pathway is involved in the protective effects of salvianolate. TAOC levels were significantly reduced in H2O2-treated cardiomyocytes, which was enhanced by salvianolate administration (3.94 U/mg protein in control, 2.32 U/mg protein in H2O2-treated cells and 3.17 U/mg protein in 0.05 g/L salvianolate-treated cells); however, when TGFβ1 was blocked, the increase in TAOC was not observed (Figure 2D). In this study, we report that salvianolate can maintain or even improve cell viability under external stimulation. Additionally, salvianolate can reverse the adverse effects of H2O2 stimulation by inhibiting H2O2-mediated ROS and iNOS production, increasing the levels of TAOC and NO, and downregulating increased Smad2/3 and TGFβ1 expression. Notably, blockage of TGFβ1 with its antibody depletes the protective effect of salvianolate, suggesting that this effect is mediated by the TGFβ1 signaling pathway. The chronic release of ROS has been recently linked to the development of left ventricular hypertrophy and heart failure progression8, and appears to derive from nonphagocytic NAD(P)H oxidase and mitochondria. The fibrosis, collagen deposition, and metalloproteinase activation involved in the remodeling of the failing myocardium are all dependent on ROS released during the phenotypic transformation of fibroblasts to myofibroblasts associated with the progression of end-stage heart failure8,9,10,11. TGFβ1 stimulates the production of ROS in various types of nonphagocytic cells, such as endothelial cells, epithelial cells, smooth muscle cells, and fibroblasts12,13. The ROS pathway has been shown to play an important role in TGFβ1-induced fibronectin and PAI-1 upregulation in NRK-52E cells14. Our results show that TGFβ1 levels changed consistently with ROS production. More importantly, the inhibition of TGFβ1 by its antibody abolished the decrease of ROS, suggesting that the interaction between ROS and TGFβ1 was involved in the mechanism behind the effect of salvianolate on cardiomyocytes. The beneficial effects of salvianolate have been reported previously. However, our replicable and compelling cell viability data indicate that high concentrations of salvianolate are potentially toxic to cells, although other data including ELISA, Western blotting, and cell culture medium detection did not provide any direct evidence that the TGFβ pathway was involved in these toxic effects. Salvianolate, combined with other medications, reduced glutathione in the progression of chronic renal failure in patients with chronic kidney diseases. Salvianolate can reduce the extent of postoperative intestinal adhesions, decrease the expression of IL-1β and TNF-α and inhibit the hyperplasia of fibrous connective tissue15. Salvianolate can reduce endotoxin levels, restore intestinal mucosal injury, and inhibit the expression of TNF-α and IL-6 in the small intestine of cirrhotic rats5. Salvianolate administered via intravenous drip can inhibit cardiomyocytic apoptosis and improve heart function AMI in pigs7. The facilitation of the migration of endothelial cells induced by monocytes by salvianolate has also been observed. Salvianolate stimulates the expression of VEGF and bFGF and their mRNA in monocytes and may induce endothelial cell migration via these two factors16. Salvianolate inhibits proliferation and endothelian release in cultured rat mesangial cells17. In this study, we reported that salvianolate may inhibit ROS production and increase the antioxidant capacity of cardiomyocytes, suggesting its potential in the treatment of chronic cardiac fibrosis.